After Apple previewed the technology earlier this week, the FDA has now given the green light to the hearing aid features of its premium AirPods.

Cancer company Oncternal Therapeutics is folding all its clinical trials and laying off staff, turning its energy toward exploring strategic alternatives such as asset sales, a merger or acquisition.

Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure.

The European Organization for Research and Treatment of Cancer (EORTC), a network of 3,800 members across 50 countries, is extending a partnership with Medidata for another four years, according to a Sept. 11 release.

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all-important population of older adults.

Shortly after a positive data drop for Eli Lilly’s efsitora alfa, the Indianapolis-based company is again padding the case for its weekly insulin prospect.

Hundreds of millions of people who live in, or are descended from, regions where the malaria-causing protozoan Plasmodium vivax is prevalent have inherited a unique blood type that evolved to prevent malaria infection. People with the Duffy null phenotype—who are primarily of African and Middle Eastern descent—have red blood cells that lack a surface protein called the Duffy antigen, which is what P. vivax uses to infect cells.

Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage trials, the pharma’s head of metabolism R&D has told Fierce Biotech.

The FDA has launched a study to examine the potential toxicity of metals that can be found within tampons—a regulated medical device, from the agency’s point of view.

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for further reductions in longer trials.